The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.
Mayo Clinic researchers conducted a study to estimate the effectiveness and safety of thyroid hormone treatment among pregnant women with subclinical hypothyroidism. Among 5405 pregnant women with subclinical hypothyroidism, 843 with a mean pre-treatment thyroid stimulating hormone (TSH) concentration of 4.8 mIU/L were treated with thyroid hormone and 4562 with a mean baseline TSH concentration of 3.3 mIU/L were not treated. Pregnancy loss was significantly less common among treated women than among untreated women. Compared with the untreated group, treated women had lower adjusted odds of pregnancy loss but higher odds of preterm delivery, gestational diabetes, and pre-eclampsia; other pregnancy related adverse outcomes were similar between the two groups. Thyroid hormone treatment was associated with decreased risk of pregnancy loss among women with subclinical hypothyroidism, especially those with pre-treatment TSH concentrations of 4.1-10 mIU/L. However, the increased risk of other pregnancy related adverse outcomes calls for additional studies evaluating the safety of thyroid hormone treatment in this patient population. The study was published in BMJ.